Hormonal
GLP-1 receptor agonists (e.g., semaglutide/Ozempic) suppress appetite and hunger signals by mimicking the hormone GLP-1, leading to significant weight loss but also causing a loss of the sensory and relational pleasure of eating.
GLP-1 drugs like semaglutide work by mimicking a hormone to reduce hunger and increase fullness, leading to weight loss. However, this comes with side effects like nausea and a reduced ability to enjoy food. The paper highlights that while these drugs can help with weight loss, they do not guarantee mental health improvements or self-acceptance, and weight regain is common if treatment stops. They are expensive and often used off-label.
Ozempic is the brand name for semaglutide... It works by mimicking a hormone called GLP-1 (glucagon-like peptide) that is triggered in response to eating (working on the brain to lead to a feeling of fullness)... Ozempic and other similar pharmaceuticals biochemically dull the 'pleasure centre' in the brain, meaning that the desire and sometimes taste for food is significantly lost.
Why this rating
The paper is a qualitative sociological analysis of marketing and discourse, not a clinical trial; it cites clinical data but does not generate primary efficacy data.
Source
Injecting care and negotiating pleasures with weight loss pharmaceuticals
Megan Warin et al. · Thesis Eleven · 2024
DOI 10.1177/07255136241285046
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →